Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190048351
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
    Type: Application
    Filed: March 5, 2018
    Publication date: February 14, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
  • Patent number: 10202603
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: February 12, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20190040395
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting KLK3 eRNA expression, which may be useful for treating, preventing, or ameliorating cancer, such as prostate cancer.
    Type: Application
    Filed: February 16, 2017
    Publication date: February 7, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Publication number: 20190040386
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Application
    Filed: July 11, 2018
    Publication date: February 7, 2019
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael Tun Yin Lam
  • Publication number: 20190016748
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Application
    Filed: February 26, 2018
    Publication date: January 17, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • Publication number: 20190017047
    Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.
    Type: Application
    Filed: May 7, 2018
    Publication date: January 17, 2019
    Applicants: Ionis Pharmaceuticals, Inc., University of Utah Research Foundation
    Inventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
  • Publication number: 20190002877
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
    Type: Application
    Filed: April 24, 2018
    Publication date: January 3, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • Publication number: 20180340178
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: February 7, 2018
    Publication date: November 29, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Publication number: 20180320188
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: May 1, 2018
    Publication date: November 8, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Publication number: 20180311365
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 1, 2018
    Inventors: Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Publication number: 20180312845
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 1, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Susan M. Freier, Eric E. Swayze
  • Patent number: 10100310
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: October 16, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • Publication number: 20180291453
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: December 18, 2017
    Publication date: October 11, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Patent number: 10093926
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: October 9, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20180273577
    Abstract: The present embodiments provide methods, compounds, and compositions for inhibiting KRAS expression, which can be useful for treating, preventing, or ameliorating a disease associated with KRAS.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 27, 2018
    Inventors: Alexey REVENKO, Susan M. FREIER, Robert A. MACLEOD
  • Publication number: 20180273946
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Application
    Filed: October 11, 2017
    Publication date: September 27, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
  • Publication number: 20180273945
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: October 5, 2017
    Publication date: September 27, 2018
    Applicants: Ionis Pharmaceuticals, Inc., CHDI Foundation, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
  • Publication number: 20180256629
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: December 27, 2017
    Publication date: September 13, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
  • Patent number: 10072265
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: September 11, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20180251761
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: January 26, 2018
    Publication date: September 6, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze